GGrantIndex
Sort

10,766 grants matching checkpoint inhibitor

A New Immune Checkpoint Pathway in Human Bladder Cancer

$545,478
Xingxing Zang · Albert Einstein College Of Medicine · R01 · FY2023 · CA

A New Immune Checkpoint Pathway in Human Bladder Cancer

$545,478
Xingxing Zang · Albert Einstein College Of Medicine · R01 · FY2025 · CA

Myct1 control of the angioimmune interface

$545,472
Kyunghee Choi · Washington University · R01 · FY2025 · CA

Identifying and targeting neoantigens in aggressive salivary carcinomas

$545,430
Luc Gordon Trang Morris · Sloan-Kettering Inst Can Research · R01 · FY2020 · DE

Cooperation of Co-Amplified Genes in Hepatocellular Carcinoma

$545,014
Devanand Sarkar · Virginia Commonwealth University · P01 · FY2024 · CA

Molecular Biology of Pediatric Tumors

$544,955
Lee J. Helman · Division Of Clinical Sciences - Nci · ZIA · FY2012 · CA

Functional Relevance of Pyrimidine Sensing and Response Pathways in Tumor Metabolism and Cancer Therapy

$544,658
Richard Lewis Possemato · New York University School Of Medicine · R01 · FY2024 · CA

Functional Relevance of Pyrimidine Sensing and Response Pathways in Tumor Metabolism and Cancer Therapy

$544,658
Richard Lewis Possemato · New York University School Of Medicine · R01 · FY2025 · CA

Understanding how T cell intrinsic androgen receptor activity influences cell differentiation and dysfunction

$544,635
Amy E Moran · Oregon Health & Science University · R37 · FY2025 · CA

Understanding how T cell intrinsic androgen receptor activity influences cell differentiation and dysfunction

$544,635
Amy E Moran · Oregon Health & Science University · R37 · FY2022 · CA

Mechanisms of Nucleic Acid Enzymes - Pol Beta, HIV-1 Reverse Transcriptase and Mammalian Base Repair Enzymes

$544,588
Samuel H Wilson · National Institute Of Environmental Health Sciences · ZIA · FY2018 · ES

Translation of commensal bacteria mechanism for immunotherapy

$544,219
Howard C Hang · Scripps Research Institute, The · R01 · FY2022 · CA

Translation of commensal bacteria mechanism for immunotherapy

$544,219
Howard C Hang · Scripps Research Institute, The · R01 · FY2023 · CA

The Role of HIF2 in Pancreatic Ductal Adenocarcinoma

$544,035
Albert Koong · University Of Tx Md Anderson Can Ctr · R01 · FY2024 · CA

Nanovaccine platforms to combat pancreatic cancer

$543,977
Balaji Narasimhan · Iowa State University · U01 · FY2018 · CA

(PQ8) Predicting immune-related toxicity in the adjuvant melanoma setting with checkpoint inhibition

$543,889
Iman Osman · New York University School Of Medicine · R01 · FY2019 · CA

Focused ultrasound-mediated intranasal brain drug delivery technique (FUSIN)

$543,721
Hong Chen · Washington University · R01 · FY2023 · EB

NR4A1 Antagonists Inhibit Colorectal Cancer Growth and Enhance Immune Surveillance

$543,717
Stephen H Safe · Texas A&M University · R01 · FY2024 · CA

Finding the optimal balance of immunotherapy efficacy and toxicity.

$543,590
David Eric Gerber · Ut Southwestern Medical Center · U01 · FY2024 · AI

Plk1 as a prognostic biomarker for prostate cancer

$543,492
Xiaoqi Liu · University Of Kentucky · R01 · FY2025 · CA

Immune epigenetic biomarkers of survival in glioma epidemiology

$543,240
John K. Wiencke · University Of California, San Francisco · R01 · FY2021 · CA

Engineered Nanoformulation for Immune-modulation in Cancer

$543,107
Rajagopal Ramesh · University Of Oklahoma Hlth Sciences Ctr · R01 · FY2023 · CA

The Role of the Y Chromosome in Bladder Tumor Development, Growth And Progression

$543,058
Dan Theodorescu · Cedars-Sinai Medical Center · P01 · FY2023 · CA

The Role of the Y Chromosome in Bladder Tumor Development, Growth And Progression

$543,058
Dan Theodorescu · Cedars-Sinai Medical Center · P01 · FY2025 · CA

Non-coding RNA regulation of Myeloid Cells

$543,051
Jorge Henao-Mejia · University Of Pennsylvania · R01 · FY2025 · CA